Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis.
<h4>Objectives</h4>To compare treatment persistence between two dosages of interferon β-1a in a large observational multiple sclerosis registry and assess disease outcomes of first line MS treatment at these dosages using propensity scoring to adjust for baseline imbalance in disease cha...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/cf363a2699c948f9a9774b6d9efd7ca3 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:cf363a2699c948f9a9774b6d9efd7ca3 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:cf363a2699c948f9a9774b6d9efd7ca32021-11-18T07:44:50ZPersistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis.1932-620310.1371/journal.pone.0063480https://doaj.org/article/cf363a2699c948f9a9774b6d9efd7ca32013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23704913/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Objectives</h4>To compare treatment persistence between two dosages of interferon β-1a in a large observational multiple sclerosis registry and assess disease outcomes of first line MS treatment at these dosages using propensity scoring to adjust for baseline imbalance in disease characteristics.<h4>Methods</h4>Treatment discontinuations were evaluated in all patients within the MSBase registry who commenced interferon β-1a SC thrice weekly (n = 4678). Furthermore, we assessed 2-year clinical outcomes in 1220 patients treated with interferon β-1a in either dosage (22 µg or 44 µg) as their first disease modifying agent, matched on propensity score calculated from pre-treatment demographic and clinical variables. A subgroup analysis was performed on 456 matched patients who also had baseline MRI variables recorded.<h4>Results</h4>Overall, 4054 treatment discontinuations were recorded in 3059 patients. The patients receiving the lower interferon dosage were more likely to discontinue treatment than those with the higher dosage (25% vs. 20% annual probability of discontinuation, respectively). This was seen in discontinuations with reasons recorded as "lack of efficacy" (3.3% vs. 1.7%), "scheduled stop" (2.2% vs. 1.3%) or without the reason recorded (16.7% vs. 13.3% annual discontinuation rate, 22 µg vs. 44 µg dosage, respectively). Propensity score was determined by treating centre and disability (score without MRI parameters) or centre, sex and number of contrast-enhancing lesions (score including MRI parameters). No differences in clinical outcomes at two years (relapse rate, time relapse-free and disability) were observed between the matched patients treated with either of the interferon dosages.<h4>Conclusions</h4>Treatment discontinuations were more common in interferon β-1a 22 µg SC thrice weekly. However, 2-year clinical outcomes did not differ between patients receiving the different dosages, thus replicating in a registry dataset derived from "real-world" database the results of the pivotal randomised trial. Propensity score matching effectively minimised baseline covariate imbalance between two directly compared sub-populations from a large observational registry.Tomas KalincikTimothy SpelmanMaria TrojanoPierre DuquetteGuillermo IzquierdoPierre GrammondAlessandra LugaresiRaymond HuppertsEdgardo CristianoVincent Van PeschFrancois Grand'maisonDaniele La SpitaleriMaria Edite RioSholmo FlechterCelia Oreja-GuevaraGiorgio GiulianiAldo SavinoMaria Pia AmatoThor PetersenRicardo Fernandez-BolanosRoberto BergamaschiGerardo IulianoCavit BozJeannette Lechner-ScottNorma DeriOrla GrayFreek VerheulMarcela FiolMichael BarnettErik van MunsterVetere SantiagoFraser MooreMark SleeMaria Laura SaladinoRaed AlroughaniCameron ShawKrisztian KasaTatjana Petkovska-BoskovaLeontien den Braber-MoerlandJoab ChapmanEli SkromneJoseph HerbertDieter PoehlauMerrilee NeedhamElizabeth Alejandra Bacile BacileWalter Oleschko ArrudaMark PaineBhim SinghalSteve VucicJose Antonio Cabrera-GomezHelmut ButzkuevenMSBase Study GroupPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 5, p e63480 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Tomas Kalincik Timothy Spelman Maria Trojano Pierre Duquette Guillermo Izquierdo Pierre Grammond Alessandra Lugaresi Raymond Hupperts Edgardo Cristiano Vincent Van Pesch Francois Grand'maison Daniele La Spitaleri Maria Edite Rio Sholmo Flechter Celia Oreja-Guevara Giorgio Giuliani Aldo Savino Maria Pia Amato Thor Petersen Ricardo Fernandez-Bolanos Roberto Bergamaschi Gerardo Iuliano Cavit Boz Jeannette Lechner-Scott Norma Deri Orla Gray Freek Verheul Marcela Fiol Michael Barnett Erik van Munster Vetere Santiago Fraser Moore Mark Slee Maria Laura Saladino Raed Alroughani Cameron Shaw Krisztian Kasa Tatjana Petkovska-Boskova Leontien den Braber-Moerland Joab Chapman Eli Skromne Joseph Herbert Dieter Poehlau Merrilee Needham Elizabeth Alejandra Bacile Bacile Walter Oleschko Arruda Mark Paine Bhim Singhal Steve Vucic Jose Antonio Cabrera-Gomez Helmut Butzkueven MSBase Study Group Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. |
| description |
<h4>Objectives</h4>To compare treatment persistence between two dosages of interferon β-1a in a large observational multiple sclerosis registry and assess disease outcomes of first line MS treatment at these dosages using propensity scoring to adjust for baseline imbalance in disease characteristics.<h4>Methods</h4>Treatment discontinuations were evaluated in all patients within the MSBase registry who commenced interferon β-1a SC thrice weekly (n = 4678). Furthermore, we assessed 2-year clinical outcomes in 1220 patients treated with interferon β-1a in either dosage (22 µg or 44 µg) as their first disease modifying agent, matched on propensity score calculated from pre-treatment demographic and clinical variables. A subgroup analysis was performed on 456 matched patients who also had baseline MRI variables recorded.<h4>Results</h4>Overall, 4054 treatment discontinuations were recorded in 3059 patients. The patients receiving the lower interferon dosage were more likely to discontinue treatment than those with the higher dosage (25% vs. 20% annual probability of discontinuation, respectively). This was seen in discontinuations with reasons recorded as "lack of efficacy" (3.3% vs. 1.7%), "scheduled stop" (2.2% vs. 1.3%) or without the reason recorded (16.7% vs. 13.3% annual discontinuation rate, 22 µg vs. 44 µg dosage, respectively). Propensity score was determined by treating centre and disability (score without MRI parameters) or centre, sex and number of contrast-enhancing lesions (score including MRI parameters). No differences in clinical outcomes at two years (relapse rate, time relapse-free and disability) were observed between the matched patients treated with either of the interferon dosages.<h4>Conclusions</h4>Treatment discontinuations were more common in interferon β-1a 22 µg SC thrice weekly. However, 2-year clinical outcomes did not differ between patients receiving the different dosages, thus replicating in a registry dataset derived from "real-world" database the results of the pivotal randomised trial. Propensity score matching effectively minimised baseline covariate imbalance between two directly compared sub-populations from a large observational registry. |
| format |
article |
| author |
Tomas Kalincik Timothy Spelman Maria Trojano Pierre Duquette Guillermo Izquierdo Pierre Grammond Alessandra Lugaresi Raymond Hupperts Edgardo Cristiano Vincent Van Pesch Francois Grand'maison Daniele La Spitaleri Maria Edite Rio Sholmo Flechter Celia Oreja-Guevara Giorgio Giuliani Aldo Savino Maria Pia Amato Thor Petersen Ricardo Fernandez-Bolanos Roberto Bergamaschi Gerardo Iuliano Cavit Boz Jeannette Lechner-Scott Norma Deri Orla Gray Freek Verheul Marcela Fiol Michael Barnett Erik van Munster Vetere Santiago Fraser Moore Mark Slee Maria Laura Saladino Raed Alroughani Cameron Shaw Krisztian Kasa Tatjana Petkovska-Boskova Leontien den Braber-Moerland Joab Chapman Eli Skromne Joseph Herbert Dieter Poehlau Merrilee Needham Elizabeth Alejandra Bacile Bacile Walter Oleschko Arruda Mark Paine Bhim Singhal Steve Vucic Jose Antonio Cabrera-Gomez Helmut Butzkueven MSBase Study Group |
| author_facet |
Tomas Kalincik Timothy Spelman Maria Trojano Pierre Duquette Guillermo Izquierdo Pierre Grammond Alessandra Lugaresi Raymond Hupperts Edgardo Cristiano Vincent Van Pesch Francois Grand'maison Daniele La Spitaleri Maria Edite Rio Sholmo Flechter Celia Oreja-Guevara Giorgio Giuliani Aldo Savino Maria Pia Amato Thor Petersen Ricardo Fernandez-Bolanos Roberto Bergamaschi Gerardo Iuliano Cavit Boz Jeannette Lechner-Scott Norma Deri Orla Gray Freek Verheul Marcela Fiol Michael Barnett Erik van Munster Vetere Santiago Fraser Moore Mark Slee Maria Laura Saladino Raed Alroughani Cameron Shaw Krisztian Kasa Tatjana Petkovska-Boskova Leontien den Braber-Moerland Joab Chapman Eli Skromne Joseph Herbert Dieter Poehlau Merrilee Needham Elizabeth Alejandra Bacile Bacile Walter Oleschko Arruda Mark Paine Bhim Singhal Steve Vucic Jose Antonio Cabrera-Gomez Helmut Butzkueven MSBase Study Group |
| author_sort |
Tomas Kalincik |
| title |
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. |
| title_short |
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. |
| title_full |
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. |
| title_fullStr |
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. |
| title_full_unstemmed |
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. |
| title_sort |
persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/cf363a2699c948f9a9774b6d9efd7ca3 |
| work_keys_str_mv |
AT tomaskalincik persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT timothyspelman persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT mariatrojano persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT pierreduquette persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT guillermoizquierdo persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT pierregrammond persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT alessandralugaresi persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT raymondhupperts persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT edgardocristiano persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT vincentvanpesch persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT francoisgrandmaison persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT danielelaspitaleri persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT mariaediterio persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT sholmoflechter persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT celiaorejaguevara persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT giorgiogiuliani persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT aldosavino persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT mariapiaamato persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT thorpetersen persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT ricardofernandezbolanos persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT robertobergamaschi persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT gerardoiuliano persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT cavitboz persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT jeannettelechnerscott persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT normaderi persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT orlagray persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT freekverheul persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT marcelafiol persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT michaelbarnett persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT erikvanmunster persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT veteresantiago persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT frasermoore persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT markslee persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT marialaurasaladino persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT raedalroughani persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT cameronshaw persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT krisztiankasa persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT tatjanapetkovskaboskova persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT leontiendenbrabermoerland persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT joabchapman persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT eliskromne persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT josephherbert persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT dieterpoehlau persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT merrileeneedham persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT elizabethalejandrabacilebacile persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT walteroleschkoarruda persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT markpaine persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT bhimsinghal persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT stevevucic persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT joseantoniocabreragomez persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT helmutbutzkueven persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis AT msbasestudygroup persistenceontherapyandpropensitymatchedoutcomecomparisonoftwosubcutaneousinterferonbeta1adosagesformultiplesclerosis |
| _version_ |
1718423063709614080 |